<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区

          Companies

          Bayer HealthCare relocates

          By Liu Jie (China Daily)
          Updated: 2011-03-25 09:44
          Large Medium Small

          Bayer HealthCare relocates

          An advertisement for White and Black, a cold medicine, in a subway station in Beijing. Bayer HealthCare bought the brand in 2006 for 100 million euros ($141 million). [Photo / China Daily] 

          The drugmaker says relocation is scheduled to be completed by June this year

          BEIJING - The pharmaceutical company Bayer HealthCare (BHC) is moving its general medicine headquarters to Beijing, which is a first among multinational drugmakers.

          "We expect this step to speed up the decision-making process and to promote more general efficiency in our day-to-day work," Chris H. Lee, the managing director of BHC China, said on Thursday. "For Chinese patients, the relocation of our general medicine headquarters will allow for more efficient product launches in China and focus greater attention on unmet local medical needs."

          BHC, a subsidiary of Germany's Bayer AG, said the decision to move was made late last year and the relocation is expected to be completed in June of this year.

          Bayer HealthCare relocates

          Chris H. Lee, managing director of BHC China?

          BHC plans to introduce some 20 new products in China over the next five years, including those in the fields of oncology, cardiology, women's healthcare, and diagnostic imaging. Two new products also will be launched this year. The company unveiled four new products and undertook 22 clinical trials in China in 2010.

          Lee said that the increasing importance of the Chinese market and BHC's rapid growth in the country had led to the relocation. The company is one of the top three multinational drugmakers in China, with sales from the business growing above the industry average at 22 percent year-on-year in 2010, according to the independent medical care researcher IMS Health.

          General drugs account for 82 percent of the company's business. In this sector, Chinese sales contribute 12 percent to the global total. "What we do in China will have an effect on other developing economies," Lee said.

          According to IMS Health, China is now the world's third-largest pharmaceutical market, and is predicted to grow between 25 percent and 27 percent to more than $50 billion in 2011.

          In addition to moving its general medicine headquarters, BHC is moving to a regionalized structure by dividing the huge Chinese market into three regions; the central China unit will be based in Beijing, southern China will be controlled from Shanghai, and the operations center for the west of the country will be located in Chengdu.

          "The strategy will enable us to be customer-centric, to disaggregate operational complexity, be more flexible, and speed up operational decision-making at the frontline. It will help us to stay close to front-line employees and be more attentive to their needs and development," said Lee.

          Currently, the central region accounts for 45 percent of the company's business in China. The southern operations make up 35 percent, and the western region 20 percent. "We believe the western region will grow faster than the others," said the managing director.

          Related readings:
          Bayer HealthCare relocates China to be 3rd largest pharma market in 2011
          Bayer HealthCare relocates China lures global drug makers
          Bayer HealthCare relocates Chinese pharma sales to boost global demand
          Bayer HealthCare relocates Lilly to continue China expansion

          The company will also strengthen its sales force by adding 1,000 positions in 2011 in its core markets and lower-tier cities.

          Despite the current enthusiasm of multinational companies for merging or acquiring local counterparts, Lee said that "at the moment" the company is "focusing on organic expansion".

          But when there are good opportunities, the company will engage in mergers and acquisitions, he added.

          "It is a sort of shortcut for the multinationals to expand their product portfolios, obtain medicines tailored for local requirements and penetrate the grassroots market," said Guo Fanli, an analyst at the China Investment Consulting.

          In the "On-The-Counter" market, BHC paid 100 million euros ($141 million) for the cough and cold medicines portfolio of the domestic drugmaker Topsun Science and Technology Co Ltd in 2006.

           

          分享按鈕
          主站蜘蛛池模板: 亚洲精品动漫免费二区| 日本在线观看高清不卡免v| 欧美拍拍视频免费大全| 久久成人国产精品免费软件| 精品国产成人亚洲午夜福利| 四虎成人在线观看免费| 中年国产丰满熟女乱子正在播放 | 国产精品专区第1页| 久久WWW免费人成看片入口| 国产乱码精品一区二三区| 欧美性69式xxxx护士| 国产精品久久福利新婚之夜| 久久精品国产福利亚洲av| 成人午夜免费一区二区三区| 国产一区二区a毛片色欲| 青青草国产自产一区二区| 亚洲色在线V中文字幕| 国产精品国产三级国AV| 上司人妻互换hd无码| 太粗太深了太紧太爽了动态图男男 | 国产精品久久久久久2021| 十八禁国产精品一区二区| 国产成年无码久久久免费| 日本MV高清在线成人高清| 无码熟妇人妻av在线电影| 久久久久国产a免费观看rela| 免费人妻无码不卡中文字幕18禁| 国产果冻豆传媒麻婆精东| 爽爽精品dvd蜜桃成熟时电影院 | 日本亚洲中文字幕不卡| 精品国产欧美一区二区三区在线| av天堂亚洲区无码先锋影音| 绝顶丰满少妇av无码| 亚洲国产性夜夜综合| 四虎永久在线精品免费视频观看| 五月国产综合视频在线观看| 日本一道一区二区视频| 久久综合国产精品一区二区 | 亚洲а∨精品天堂在线| 亚洲中文字幕国产av| 色综合久久久久综合体桃花网|